Gujarat Kidney & Super Speciality IPO targets investors seeking exposure to India's expanding super-speciality healthcare, with aggressive acquisition and expansion plans across Gujarat.​

Gujarat Kidney IPO – Key Details

5. Company: Gujarat Kidney and Super Speciality Limited
5. Focus: Super-speciality hospital chain with kidney care, multi-specialty services across Vadodara and expanding footprint.
5. IPO Type: Main-board (book-built issue).
5. IPO Open: 22 December 2025
5. IPO Close: 24 December 2025
5. Allotment: 26 December 2025
5. Total Issue size :- 2.20 cr shares
5. Refunds/Demat Credit: 29 December 2025
5. Listing: 30 December 2025 (BSE/NSE)
5. Anchor Date: 19 December 2025​

Promoters: Dr. Pragnesh Yashwantsinh Bharpoda, Dr. Bhartiben Pragnesh Bharpoda, Dr. Yashwantsingh Motisinh Bharpoda, Anitaben Yashwantsinh Bharpoda.
Promoter Holding: 99.10% pre-issue (post-issue details in final RHP).​

Business & Financial Snapshot

Gujarat Kidney operates super-speciality hospitals focusing on nephrology, urology and multi-specialty care, with plans for rapid expansion through acquisitions and greenfield projects in Gujarat's key cities.​

Gujarat Kidney & Super Speciality Ltd.'s revenue increased by 637% and profit after tax (PAT) rose by 454% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended	30 Jun 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	61.59	55.34	20.53	3.87
Total Income	15.27	40.40	5.48	0.00
Profit After Tax	5.40	9.50	1.71	-0.01
EBITDA	8.63	16.55	1.95	-0.01
NET Worth	30.56	25.71	10.80	0.37
Reserves and Surplus	19.42	14.57	10.60	0.17
Total Borrowing	4.03	3.88	1.94
Amount in ₹ Crore

IPO Reservation :- QIB 75%, NII 15%, Retail 10% (standard main-board split).

Objective of the Issue (₹ crore):​

• Parekhs Hospital acquisition (Ahmedabad): ₹77.00
• Ashwini Medical Centre payment: ₹12.40
• New hospital in Vadodara: ₹30.10
• Robotics equipment: ₹6.83
• Debt repayment: ₹1.20
• Harmony Medicare stake: ₹10.78
• Inorganic growth/general purposes

Key Strengths

• Exceptional revenue/PAT growth FY24–FY25 (40x revenue jump)
• High EBITDA (41%) and PAT margins (23.6%) for hospital business
• Clear inorganic growth via hospital acquisitions
• Strong Q1 FY26 momentum (PAT ₹5.4cr)
• Low debt (0.15 debt-equity) with repayment plan
• Doctor-promoters with clinical expertise

Key Risks

• Very short revenue track record (FY23 near-zero)
• Heavy reliance on acquisitions for growth
• High execution risk in new Vadodara hospital/robotics
• Regional concentration in Gujarat healthcare
• Main-board IPO with 10% retail quota (tough allotment)
• Premium valuation vs established hospital peers

How To Apply for the IPO ?

• Login or Open demat account with JM Financial Services / JM PRO app: Open the JM PRO app or JM Financial Services website and log in with your credentials. 
• Locate the IPO Section: Navigate to the 'IPO' section on the platform. 
• Select IPO: Find and select the IPO from the list of open IPOs. 
• Enter the Lot Size: Specify the number of lots you want to bid for. 
• Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application. 
• Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN. 

How To Check the Allotment Status of IPO?

Steps to check IPO allotment status on JM Pro app: 

• Log in to the JM Pro app. 
• Go to the IPO Section and then to IPO Orders. 
• Select the individual IPO that you had applied for and check the allotment status. 

JM Financial Services will notify you of your IPO allotment status via push notification and email

 

FAQs – Gujarat Kidney IPO

Q1. What are Gujarat Kidney IPO dates?
A: Opens 22 December 2025, closes 24 December 2025; allotment 26 December; listing 30 December 2025.​

Q2. How is the issue reserved?
A: QIB 75%, NII 15%, Retail 10% (main-board norms).​

Q3. What are main IPO uses?
A: Parekhs Hospital acquisition (₹77cr), Ashwini Medical payment (₹12.4cr), Vadodara hospital (₹30.1cr), robotics (₹6.83cr), debt repayment (₹1.2cr).​

Q4. How strong are FY25 financials?
A: Revenue ₹40.4cr, PAT ₹9.5cr, EBITDA margin 41%, ROE 36.6%, debt-equity 0.15.​

Q5. Who are promoters?
A: Doctor family – Dr. Pragnesh Bharpoda, Dr. Bhartiben Bharpoda, Dr. Yashwantsinh Bharpoda, Anitaben Bharpoda (99.1% pre-issue holding).​